Sign up Australia
Proactive Investors - Run By Investors For Investors

MMJ Phytotech invests into major Canadian medical cannabis company

The C$5 million investment gives MMJ a 6.9% interest in MediPharm Labs Inc.
Cannabis growing facility
MMJ has a diversified portfolio of cannabis sector investments

MMJ PhytoTech Ltd (ASX:MMJ) has invested C$5 million for a 6.9% basic shareholding in MediPharm Labs Inc, which owns Canada’s largest medical cannabis oil production facility.

MMJ is a global cannabis investment company with a diversified portfolio of cannabis sector investments.

READ: MMJ PhytoTech invests into global cannabis lifestyle brand

It has made a number of recent investments with Ontario-based MediPharm Labs representing the ninth.

As well as the production facility supporting 100,000 kilograms of annual dry cannabis processing, MediPharm owns a majority share in MediPharm Labs Australia.

Australian operation

This operation, which is based in Wonthaggi, Victoria, has lodged a cannabis manufacturing licence application.

MMJ’s CEO Jason Conroy said: “As Canada’s largest medical cannabis oil production facility and with a strategic presence in Australia, MediPharm is strongly positioned to capitalise on growth opportunities in Canada and overseas.”

ACMPR licensed producer

MediPharm is an Access to Cannabis for Medical Purposes Regulations (ACMPR) licensed producer for the production of cannabis oil and expects to receive a sales licence later this year.

It uses innovative extraction technologies that create products designed for specific patient solutions and has manufacturing and distribution partnerships with proven patented formulators.

MediPharm is strongly positioned to capitalise on Canadian medical cannabis oil market sales growth, both for domestic patients and for export.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full MMJ profile View Profile

MMJ PhytoTech Timeline

Newswire
December 11 2017
Newswire
November 10 2017

Related Articles

scientist in lab
September 11 2018
The phase 1b trial of Silence’s lead candidate, SLN124, a treatment for a rare blood disorder, is scheduled to begin in the second half of 2019
mountains
August 22 2018
So far, the hit rate is a five out of 12 success rate for its investments
immunotherapy graphic
September 13 2018
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use